Proprietary Aquablation Technology: Procept Biorobotics' core competitive edge lies in its proprietary AquaBeam Robotic System, which utilizes a heat-free, robot-assisted waterjet to precisely ablate prostate tissue, offering a unique and differentiated approach to BPH treatment.

Strong Clinical Efficacy and Safety Profile: The company boasts robust clinical data demonstrating superior outcomes in BPH treatment, including sustained symptom relief, durable results, and a favorable safety profile with a low rate of complications such as sexual dysfunction and incontinence compared to traditional surgical methods.

Extensive Intellectual Property Portfolio: Procept Biorobotics holds a substantial number of patents and pending applications protecting its Aquablation therapy and AquaBeam system, creating significant barriers to entry for potential competitors and safeguarding its technological innovation.